What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy;…
What is Taysha Gene Therapies, Inc.'s P/E and P/B ratio?
Taysha Gene Therapies, Inc. has a P/E ratio of -9.7 and a P/B ratio of 3.33.
What is Taysha Gene Therapies, Inc.'s debt-to-equity ratio?
Taysha Gene Therapies, Inc. has a debt-to-equity ratio of 0.15.
How much does Taysha Gene Therapies, Inc. owe compared with what it owns?
Taysha Gene Therapies, Inc. owes $0.18 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Taysha Gene Therapies, Inc.'s Positivity rank?
Taysha Gene Therapies, Inc. is ranked #4,182 of 6,775 companies globally and #2,012 of 3,999 in United States on PositoAI, with a Positivity Score of 19,844.
Does Taysha Gene Therapies, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Taysha Gene Therapies, Inc..
Where can I read the latest news about Taysha Gene Therapies, Inc.?
Recent headlines about Taysha Gene Therapies, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Taysha Gene Therapies, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Taysha Gene Therapies, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.